Chen Yi-Wei, Huang Pin-I, Hu Yu-Wen, Ho Donald Ming-Tak, Chang Kai-Ping, Guo Wan-Yuo, Chang Feng-Chi, Lee Yi-Yen, Shiau Cheng-Ying, Wong Tai-Tong, Yen Sang-Hue
Division of Radiation Oncology, Cancer Center, Neurological Institute, Taipei Veterans General Hospital, Taipei 112, Taiwan.
Childs Nerv Syst. 2012 Apr;28(4):557-63. doi: 10.1007/s00381-012-1683-2. Epub 2012 Jan 13.
Initially disseminated intracranial germinomas (IDIGs) can be observed in pre-adult and adolescent brain tumor patients. However, the disease prognosis is undetermined, and the method of optimal treatment remains controversial.
From January 1990 to January 2011, data on 91 intracranial germinoma patients (≤20 years old) were gathered from the Pediatric Brain Tumor database at Taipei Veterans General Hospital. A total of seven patients with a median age of 17.0 years had IDIGs (lesion sites >2), including IDIGs in the ventricular system or the spinal column. Craniospinal irradiation (CSI) plus a primary or metastatic boost was the mainstay strategy for radiotherapy. Six out of a total of seven patients (85.7%) also received systemic chemotherapy (CHT) after radiotherapy. Survivals rates between IDIGs and patients without dissemination were estimated using the Kaplan-Meier method.
The median follow-up time for all seven patients was 67.5 months (range, 10.3-142.3 months). None of the IDIG patients experienced a recurrence or mortality after the completion of treatment. The 5- and 10-year disease-free survival (DFS) between IDIG and non-dissemination patients were 100%, 100%, 93.0% and 78.6%, respectively (p = 0.339). The 5- and 10-year overall survival (OS) between IDIGs and non-dissemination cases were 100%, 100%, 93.7% and 89.4%, respectively (p = 0.473).
IDIG patients did not show reduced survival compared to non-dissemination patients if optimal radiotherapy and chemotherapy were used together.
最初播散性颅内生殖细胞瘤(IDIGs)可见于成年前和青少年脑肿瘤患者。然而,该病的预后尚无定论,最佳治疗方法仍存在争议。
1990年1月至2011年1月,从台北荣民总医院儿科脑肿瘤数据库收集了91例颅内生殖细胞瘤患者(≤20岁)的数据。共有7例中位年龄为17.0岁的患者患有IDIGs(病变部位>2个),包括脑室系统或脊柱中的IDIGs。全脑脊髓照射(CSI)加原发灶或转移灶推量照射是放疗的主要策略。7例患者中有6例(85.7%)在放疗后也接受了全身化疗(CHT)。使用Kaplan-Meier方法估计IDIGs患者与未播散患者的生存率。
所有7例患者的中位随访时间为67.5个月(范围10.3 - 142.3个月)。所有IDIG患者在完成治疗后均未出现复发或死亡。IDIG患者与未播散患者的5年和10年无病生存率(DFS)分别为100%、100%、93.0%和78.6%(p = 0.339)。IDIG患者与未播散患者的5年和10年总生存率(OS)分别为100%、100%、93.7%和89.4%(p = 0.473)。
如果联合使用最佳放疗和化疗,IDIG患者与未播散患者相比生存率并未降低。